Kidney Therapeutics: Translating Discoveries into Prevention, Treatment and Cures for Kidney Diseases

整体组件的项目摘要 尽管最近的发现解释了一些肾脏疾病的分子发病机制，但新的 治疗方法出现得很慢。令人震惊的3000万美国人患有肾脏疾病， 目前迫切需要促进新疗法的开发，但尚未得到满足。建议的总主题是 西北乔治·M·奥布莱恩肾脏核心中心名为Nu-GoKidney，将专注于肾脏 治疗学--将发现转化为预防、治疗和治愈。要实现这一目标，需要 多个科学和临床学科之间广泛而富有成效的合作，而不是 传统上是互动的。我们的中心将联合三个核心的研究人员：临床前模型核心 (核心A)、治疗发展核心(核心B)和临床和翻译核心(核心 c)。该中心将培养西北大学独特的、无与伦比的人才来实现这一目标 目标，包括：1)一批杰出的跨学科肾脏研究人员；2)收集大量相关的 动物模型和细胞系；3)世界领先的纳米医学研究所；4)创新的世界级 致力于药物发现的化学系；5)世界领先的生物电子学专业知识；6)著名的 药物基因组学和药理学专家团队；7)高水平的良好制造规范 (GMP)由核心董事之一开发的生产设施；8)电子数据仓库，包括 670万与基因组数据相关的个体患者；9)大型肾脏标本生物库；10)专业知识和 进行首次人体研究的基础设施；11)社区参与进行研究的记录 研究和12)创新和新风险投资办公室(INVO)。除了成立了三个 作为生物医学核心，Nu-GoKidney中心将支持创新的浓缩项目和试点 旨在加强跨学科合作的可行性研究，吸引新的调查人员 肾脏疾病领域，培养下一代肾脏创新者。一个在线门户网站niro-Hub将 首次向外界提供对这些独特的NU资源的访问和肾脏治疗 将推出加速器以促进西北地区的治疗创新和催化翻译 以及整个芝加哥、国家和国际肾脏社区。

PROJECT SUMMARY TO OVERALL COMPONENT Despite recent discoveries that explain the molecular pathogenesis of a number of kidney diseases, new therapies have been slow to emerge. With a staggering 30 million Americans suffering from kidney diseases, there is an urgent unmet need to facilitate development of new treatments. The overall theme of the proposed Northwestern George M. O’Brien Kidney Core Center named NU-GoKIDNEY, will focus on Kidney Therapeutics – to translate discoveries into prevention, treatment and cures. To realize this objective, requires extensive and productive collaborations between multiple scientific and clinical disciplines that do not traditionally interact. Our Center will unite investigators across three Cores: the Pre-Clinical Models Core (Core A), the Therapeutics Development Core (Core B) and the Clinical and Translational Core (Core C). The Center will nucleate unique, unparalleled talent available at Northwestern University to accomplish this goal, including: 1) an exceptional group of interdisciplinary kidney researchers; 2) large collection of relevant animal models and cell lines; 3) a world-leading nanomedicine institute; 4) an innovative and world-class chemistry department devoted to drug discovery; 5) world-leading bio-electronics expertise; 6) a renowned team of experts in pharmacogenomics and pharmacology; 7) a high level Good Manufacturing Practices (GMP) production facility developed by one of the core directors; 8) an electronic data warehouse comprising 6.7M individual patients linked to genomic data; 9) large biorepository of renal specimens; 10) expertise and infrastructure to conduct first-in-human studies; 11) track record of community engagement in the conduct of research and 12) an Innovation and New Ventures office (INVO). In addition to the establishment of the three biomedical cores, the NU-GoKIDNEY Center will support innovative Enrichment programs and Pilot and Feasibility studies designed to enhance cross-disciplinary collaborations, attract new investigators into the kidney diseases field and train the next generation of kidney innovators. An online portal nephro-HUB will provide access to these unique NU resources - for the first time - to the outside world and a Kidney Cure Accelerator will be launched to promote therapeutic innovation and catalyse translation within Northwestern and across the Chicagoland, national and international kidney communities.